Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977779 | 0.85 | TP53 (0.49) | HDAC6ALOX15MEN1KMT2ATP53 | |
| SCHEMBL23051194 | 0.83 | KDM4E (0.45) | HDAC6ALOX15MEN1KMT2ATP53 | |
| SCHEMBL981580 | 0.81 | TP53 (0.52) | HDAC6ALOX15MEN1KMT2ATP53 | |
| SCHEMBL26054575 | 0.77 | CA9 (0.53) | ALOX15MEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL16722810 | 0.74 | CES2 (0.46) | ALOX15MEN1KMT2ATP53SMN1; SMN2 | |
| SCHEMBL979646 | 0.74 | TP53 (0.48) | TP53CA2KDM4ELMNAMAOA | |
| SCHEMBL12640272 | 0.74 | ALDH1A1 (0.41) | HDAC6TP53CLK1DYRK1ADYRK1B | |
| SCHEMBL12597509 | 0.73 | CTNNB1 (0.55) | — | |
| SCHEMBL12795524 | 0.73 | LMNA (0.51) | TP53CLK1DYRK1ADYRK1BSMN1; SMN2 | |
| SCHEMBL28320126 | 0.73 | TP53 (0.47) | TP53CLK1DYRK1ADYRK1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | PFIZER INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210061923-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | PFIZER INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-10870706-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | PFIZER INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10391182-B2 | Bifunctional cytotoxic agents | PFIZER INC. (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061923-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | CCNI, TTI1, TTI2 | HDAC6 2147/4885ALOX15 2536/4885MEN1 620/4885 |
| US-10870706-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | CCNI, TTI1, TTI2 | HDAC6 2147/4885ALOX15 2536/4885MEN1 620/4885 |
| US-10391182-B2 | Bifunctional cytotoxic agents | PAICS, CYTH3, CYTH2 | HDAC6 616/4885ALOX15 3596/4885MEN1 3380/4885 |
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | CCNI, TTI1, TTI2 | HDAC6 2147/4885ALOX15 2536/4885MEN1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.